A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

November 4, 2026 updated by: Shanghai Junshi Bioscience Co., Ltd.

A Phase II Study of JS212 Monotherapy or Combination Therapy With JS207 or JS001 in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.

Study Overview

Detailed Description

The study consists of 2 parts. Both parts consist of safety run-in period and cohort expansion period. Safety run-in period will enroll those who have received only 1 line of prior systemic standard treatment. Cohort expansion period will enroll those are treated naive or recived treatment in adjuvant phase.

Part 1 will receive JS212 monotherapy or combination therapy with JS207, based on the PD-L1 expression. Part 2 will receive JS212 in combination with JS001.

Study Type

Interventional

Enrollment (Estimated)

184

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Beijing, China
        • Recruiting
        • Peking University People's Hospital
        • Contact:
        • Principal Investigator:
          • Shu Wang, Ph.D.
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100144
        • Not yet recruiting
        • Peking University Shougang Hospital
        • Contact:
        • Principal Investigator:
          • Xueli Mo, Master
      • Beijing, Beijing Municipality, China, 100071
        • Not yet recruiting
        • The Fifth Medical Center of Chinese PLA General Hospital
        • Contact:
        • Principal Investigator:
          • Shaohua Zhang, Doctor
    • Fujian
      • Fuzhou, Fujian, China, 350000
        • Not yet recruiting
        • Fujian Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Fan Wu, Ph.D.
    • Gansu
      • Lanzhou, Gansu, China, 730000
        • Not yet recruiting
        • The First Hospital of Lanzhou University
        • Contact:
        • Principal Investigator:
          • Xiaoling Ling, Ph.D.
    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • Not yet recruiting
        • Sun Yat-sen University Cancer Center
        • Contact:
        • Principal Investigator:
          • Shusen Wang, Ph.D.
      • Guangzhou, Guangdong, China, 510080
        • Not yet recruiting
        • Guangdong General Hospital
        • Contact:
        • Principal Investigator:
          • Kun Wang, Ph.D.
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Not yet recruiting
        • The Affiliated Hospital of Guizhou Medical University
        • Contact:
        • Principal Investigator:
          • Shu Liu, Ph.D.
      • Guiyang, Guizhou, China, 550001
        • Not yet recruiting
        • The Affiliated Cancer Hospital of Guizhou Medical University City: Guiyang
        • Contact:
        • Principal Investigator:
          • Zhihong Wang, Bachelor
    • Hebei
      • Baoding, Hebei, China, 071000
        • Not yet recruiting
        • Affiliated Hospital of Hebei University
        • Contact:
        • Principal Investigator:
          • Hua Yang, Ph.D.
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150081
        • Not yet recruiting
        • Harbin Medical University Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Wenhui Zhao, Ph.D.
    • Henan
      • Zhengzhou, Henan, China, 450001
        • Not yet recruiting
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
        • Principal Investigator:
          • Hong Zong, Ph.D.
      • Zhengzhou, Henan, China, 450002
        • Not yet recruiting
        • Henan Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Min Yan, Ph.D.
    • Hubei
      • Wuhan, Hubei, China, 430079
        • Not yet recruiting
        • Hubei Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Xinhong Wu, Ph.D.
    • Hunan
      • Changde, Hunan, China, 415003
        • Not yet recruiting
        • The First People's Hospital of Changde City
        • Contact:
        • Principal Investigator:
          • Hui Li, Ph.D.
      • Changsha, Hunan, China, 410013
        • Not yet recruiting
        • Hunan Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Quchang Ouyang, Ph.D.
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Not yet recruiting
        • Jiangsu Province Hospital
        • Contact:
        • Principal Investigator:
          • Wei Li, Ph.D.
    • Jiangxi
      • Nanchang, Jiangxi, China, 330009
        • Not yet recruiting
        • Nanchang People's Hospital
        • Contact:
        • Principal Investigator:
          • Wenyan Chen, Bachelor
    • Jilin
      • Changchun, Jilin, China, 130021
        • Not yet recruiting
        • The First Hospital of Jilin University
        • Contact:
        • Principal Investigator:
          • Lihua Kang, Ph.D.
      • Changchun, Jilin, China, 130012
        • Not yet recruiting
        • Jilin Provincial Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Fei Chen, Master
    • Liaoning
      • Shenyang, Liaoning, China, 110022
        • Not yet recruiting
        • Shengjing Hospital of China Medical University
        • Contact:
        • Principal Investigator:
          • Xihe Zhao, Ph.D.
      • Shenyang, Liaoning, China, 110042
        • Not yet recruiting
        • Cancer Hospital of Dalian University of Technology(Liaoning Cancer Hospital & Institute)
        • Contact:
        • Principal Investigator:
          • Tao Sun, Ph.D.
      • Shenyang, Liaoning, China, 110167
        • Not yet recruiting
        • Introduction to the First Affiliated Hospital of China Medical University
        • Contact:
        • Principal Investigator:
          • Yuee Teng, Ph.D.
    • Ningxia
      • Yinchuan, Ningxia, China, 750000
        • Not yet recruiting
        • General Hospital of Ningxia Medical University
        • Contact:
        • Principal Investigator:
          • Ye Lv, Bachelor
    • Shandong
      • Jinan, Shandong, China, 250117
        • Not yet recruiting
        • Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
        • Contact:
        • Contact:
        • Principal Investigator:
          • Huihui Li, Ph.D.
      • Jining, Shandong, China, 272000
        • Not yet recruiting
        • Affiliated Hospital of Jining Medical University
        • Contact:
        • Principal Investigator:
          • Changping Shan, Master
      • Qingdao, Shandong, China, 266000
        • Not yet recruiting
        • The Affiliated Hospital of Qingdao University
        • Contact:
        • Principal Investigator:
          • Haibo Wang, Ph.D.
      • Weifang, Shandong, China, 261000
        • Not yet recruiting
        • Weifang People's Hospital
        • Contact:
        • Principal Investigator:
          • Wenhui Wang, Ph.D.
    • Shanxi
      • Taiyuan, Shanxi, China, 030013
        • Not yet recruiting
        • Shanxi Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Guohui Han, Ph.D.
    • Sichuan
      • Chengdu, Sichuan, China, 610072
        • Not yet recruiting
        • Sichuan Provincial People's Hospital
        • Contact:
        • Principal Investigator:
          • Jing Luo, Ph.D.
      • Mianyang, Sichuan, China
        • Not yet recruiting
        • Mianyang Central Hospital
        • Contact:
        • Principal Investigator:
          • Zhen Zhang, Master

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or female age 18-70 years old;
  2. Voluntary participation in clinical study;
  3. Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
  4. No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC;
  5. Adequate organ function;
  6. ECOG performance status of 0 or 1;
  7. Life expectancy 12 weeks;
  8. Measurable disease, as defined by RECIST v1.1;

Exclusion Criteria:

  1. Untreated or active central nervous system (CNS) metastases;
  2. Uncontrolled pleural effusion, pericardial effusion or ascites;
  3. Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage;
  4. History of significant bleeding tendency or severe coagulation disorder;
  5. Uncontrolled hypertension;
  6. Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose;
  7. History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period;
  8. History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C;
  9. Severe cardiovascular disease;
  10. Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug;
  11. Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;
  12. History of another malignancy within 5 years before the first dose of study drug;
  13. Not suitable to receive study treatment for other conditions as per investigator;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort A

JS212 in combination with JS207,CPS≥10

JS212 and JS207 will be administered intravenously on D1, Q3W

Experimental: Cohort B

JS212 monotherapy, CPS<10

JS212 will be administered intravenously on D1,Q3W

Experimental: Cohort C

JS212 in combination with JS207, CPS<10

JS212 and JS207 will be administered intravenously on D1, Q3W

Experimental: Cohort D

JS212 in combination with JS001

JS212 and JS001 will be administered intravenously on D1, Q3W

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate(ORR)
Time Frame: 24 months

Objective response rate(ORR) evaluated based on RECIST v1.1

24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of response (DoR)
Time Frame: 24 months

Duration of response (DoR) evaluated based on RECIST v1.1

24 months
Disease control rate (DOR)
Time Frame: 24 months

Disease control rate (DOR)evaluated based on RECIST v1.1

24 months
Progression free survival (PFS)
Time Frame: 24 months

Progression free survival (PFS) evaluated based on RECIST v1.1

24 months
Overall Survival (OS)
Time Frame: 36 months

Overall Survival (OS)evaluated based on RECIST v1.1

36 months
Adverse Events
Time Frame: 24 months

Incidence and severity of Adverse Events(AEs)according to NCI-CTCAE v6.0

24 months
Immunogenicity
Time Frame: 24 months

The incidence of Nab(if applicable) of JS212 and JS207

24 months
Plasma concentrations
Time Frame: 2 years

Plasma concentrations of JS207 and 9MW2821

2 years
PD-L1 expression
Time Frame: 2 years

The correlation between PD-L1 expression in tumor tissue and therapeutic efficacy

2 years
EGFR/HER expression
Time Frame: 2 years

The correlation between EGFR/HER3 expression in tumor tissue and therapeutic efficacy

2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 22, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

March 5, 2029

Study Registration Dates

First Submitted

October 9, 2026

First Submitted That Met QC Criteria

October 9, 2026

First Posted (Actual)

October 15, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe